Global sales for the treatment of erectile dysfunction and premature ejaculation are estimated to be around USD 8 billion in 2023. Sales of existing treatments are expected to grow by over 50% by 2029.

Market growth is high due to an aging population, increased prevalence of underlying diseases such as diabetes, and increased accessibility through digital healthcare providers.

PDE5 inhibitors, which include Viagra, are the most common drugs used to treat erectile dysfunction on the market today and were a revolution when they were introduced in the late 1990s. However, they have their limitations, and little has happened on the market since then. There is a clear need for new pharmaceuticals with longer lasting effect, fewer side effects and that provide treatment for patient groups that are not currently helped by PDE5 inhibitors.

For premature ejaculation, there are currently few effective treatments on the market.

Dicot's drug candidate is intended to be marketed for the treatment of both dysfunctions, both separately and in combination. As far as Dicot is aware, such treatment of both conditions simultaneously would be unique. The Phase 1 study has been conducted for the indication of erectile dysfunction.